Natus Medical Incorporated (NASDAQ:NTUS) Stock Holdings Increased by First Horizon Advisors Inc.

First Horizon Advisors Inc. boosted its position in Natus Medical Incorporated (NASDAQ:NTUSGet Rating) by 1,529.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,581 shares of the company’s stock after buying an additional 1,484 shares during the period. First Horizon Advisors Inc.’s holdings in Natus Medical were worth $37,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. UMB Bank N A MO bought a new stake in Natus Medical in the fourth quarter valued at about $29,000. Dimensional Fund Advisors LP increased its holdings in Natus Medical by 1.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,316,697 shares of the company’s stock valued at $31,245,000 after buying an additional 12,655 shares during the last quarter. Factorial Partners LLC increased its holdings in Natus Medical by 3.4% in the fourth quarter. Factorial Partners LLC now owns 40,100 shares of the company’s stock valued at $952,000 after buying an additional 1,300 shares during the last quarter. Baird Financial Group Inc. increased its holdings in Natus Medical by 10.8% in the fourth quarter. Baird Financial Group Inc. now owns 12,971 shares of the company’s stock valued at $308,000 after buying an additional 1,265 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in Natus Medical in the fourth quarter valued at approximately $200,000. 92.35% of the stock is owned by hedge funds and other institutional investors.

Shares of NTUS stock opened at $32.57 on Friday. Natus Medical Incorporated has a 1 year low of $20.90 and a 1 year high of $33.93. The stock has a market cap of $1.13 billion, a PE ratio of 88.03 and a beta of 0.23. The business’s fifty day moving average is $28.61 and its 200-day moving average is $25.81.

Natus Medical (NASDAQ:NTUSGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.04). Natus Medical had a net margin of 2.65% and a return on equity of 10.15%. During the same period last year, the firm earned $0.16 EPS. As a group, sell-side analysts predict that Natus Medical Incorporated will post 1.44 EPS for the current year.

Several equities analysts have recently issued reports on NTUS shares. Zacks Investment Research cut Natus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, May 3rd. StockNews.com started coverage on Natus Medical in a research report on Thursday, March 31st. They set a “strong-buy” rating on the stock.

Natus Medical Company Profile (Get Rating)

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases.

Further Reading

Want to see what other hedge funds are holding NTUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:NTUSGet Rating).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:NTUS)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.